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Abstract 138 
IMPORTANCE: Collaborative care is an intensive care model involving a number of 139 
healthcare professionals working together, typically a medical doctor, a case manager, 140 
and a mental health professional. Meta-analyses of aggregate data have shown that 141 
collaborative care is particularly effective in people with depression and comorbid 142 
chronic physical conditions. However, only participant-level analyses can rigorously test 143 
whether the treatment effect is influenced by participant characteristics such as chronic 144 
physical conditions. 145 
OBJECTIVE: To assess whether the effectiveness of collaborative care for depression is 146 
moderated by the presence, type, and number of chronic physical conditions.  147 
DATA SOURCES: Medline, Embase, Pubmed, PsycINFO, Cinahl, and Central, and 148 
references from relevant systematic reviews.  149 
STUDY SELECTION: Randomized controlled trials that compared the effectiveness of 150 
collaborative care with usual care in adults with depression. Measured change in 151 
depression severity symptoms at 4 to 6 months post-randomization.  152 
DATA EXTRACTION AND SYNTHESIS: Individual participant data on baseline 153 
demographics and chronic physical conditions and baseline and follow-up depression 154 
severity symptoms were requested from authors of the eligible studies. One-step meta-155 
analysis of individual participant data using appropriate mixed-effects models was 156 
performed. 157 
MAIN OUTCOMES AND MEASURE: Continuous outcomes of depression severity 158 
symptoms measured using self-reported or observer-rated measures.  159 
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RESULTS: Datasets from 31 randomized controlled trials including 36 independent 160 
comparisons (n= 10,962 participants) were analyzed. At study-level, trials which 161 
explicitly identified participants with chronic physical conditions produced larger 162 
treatment effects compared with trials which did not explicitly identify participants with 163 
chronic physical conditions (interaction coefficient -0.12, 95% CI= -0.23 to -0.02). When 164 
individual participant data analyses, which are more powerful, were performed, no 165 
significant interaction effects were found indicating that the presence (interaction 166 
coefficient = 0.02, 95% CI= -0.10 to 0.13), numbers (interaction coefficient = 0.01, 95% 167 
CI= -0.01 to 0.02) and types of chronic physical conditions do not influence the 168 
treatment effect.  169 
CONCLUSION: There is compelling evidence that collaborative care is effective for 170 
people with depression alone and also for people with depression and chronic physical 171 
conditions. Existing guidance that recommends limiting collaborative care to people with 172 
depression and physical comorbidities is not supported by this individual participant data 173 
meta-analysis.  174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
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Background 183 
Depression is the leading global cause of disease burden accounting for most disability 184 
adjusted life years.1,2  The combination of depression with a chronic physical condition 185 
(physical condition hereafter) such as cardiovascular diseases, respiratory diseases, and 186 
diabetes is associated with the greatest decrements in quality of life, years lost due to 187 
disability,3 patient safety failures, and unscheduled care.4-8 188 
 189 
A promising intervention for depression in primary care is ‘collaborative care’,9 which 190 
involves the use of a case manager (usually non-medical but also medical e.g. clinical 191 
social workers) working with primary care professionals, often supervised by a mental 192 
health specialist and supported by care management systems. A Cochrane review 193 
showed that collaborative care is more effective than usual care for depression.10 194 
 195 
Finding feasible and effective ways of integrating care for patients with depression and 196 
comorbid physical conditions remains a critical goal for health systems worldwide. 197 
There has been significant interest in the ability of collaborative care to improve care for 198 
people with depression and physical conditions.11,12 In the United States the Community 199 
Preventive Services Task Force recommends collaborative care for the treatment of 200 
major depression in adults but concedes that there are evidence gaps about the 201 
effectiveness of this approach in people with comorbid physical conditions.13,14 In the 202 
UK, the English organization responsible for clinical guidelines (National Institute for 203 
Health and Care Excellence - NICE) recommends that collaborative care should be 204 
considered only for people with depression and comorbid physical conditions based on 205 
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results from aggregate-data meta-analyses of two sets of trials – collaborative care for 206 
patients with depression, and collaborative care for patients with depression and 207 
physical conditions.15 Although these recommendations were based on the best available 208 
evidence at the time, conducting two separate meta-analyses means that any differences 209 
in effectiveness may be confounded by differences between the trials (e.g. location, 210 
quality, intervention format) and may not be due physical conditions.16  Additionally, 211 
some collaborative care trials that recruited people with depression would not 212 
necessarily have excluded those with physical conditions, especially trials conducted in 213 
older populations where such conditions are highly prevalent.17-25  214 
 215 
To reach international consensus about the most effective ways to manage depression it 216 
is critical that guidelines reflect the most robust analysis of the most current data. There 217 
is increasing recognition that individual participant data (IPD) meta-analysis is a better 218 
basis for modelling treatment effects than aggregate data meta-analyses.26 IPD meta-219 
analysis is more precise because it involves the application of standardized analyses 220 
across multiple datasets, overcomes sample size and reporting issues, and allows more 221 
sophisticated modelling of moderator effects.26-28 In this context, IPD allows for more 222 
accurate coding of comorbidity based on actual patient health.  223 
 224 
In this study, we used IPD meta-analysis to test whether physical conditions moderate 225 
the effectiveness of collaborative care for depression outcomes. First, we examined 226 
whether studies which recruited participants with physical conditions as part of inclusion 227 
criteria demonstrated greater effect of collaborative care on depression outcomes (i.e. a 228 
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study-level moderator analysis). Subsequently, we examined whether the effectiveness of 229 
collaborative care on depression outcomes was moderated by the presence, number, 230 
and type of physical conditions reported by individual participants within trials (i.e. 231 
participant-level moderator analyses). The results will provide a rigorous basis for 232 
recommendations about the types of people most likely to benefit from collaborative 233 
care and contribute to the wider debate about how multimorbidity influences treatment 234 
effectiveness.29,30  235 
 236 
Methods 237 
This IPD meta-analysis was conducted and reported according to published 238 
methodological guidelines.31,32 The PRISMA-D was completed (eTable 1 in the 239 
Supplement). 240 
 241 
Information sources 242 
We used the published Cochrane review10 of collaborative care to identify eligible 243 
randomized controlled trials (RCTs). The Cochrane review searches were updated in 244 
March 2014 (MEDLINE, EMBASE, PsycINFO, CENTRAL and CINAHL) but search and 245 
collection of eligible studies was ongoing until May 2015. The reference lists of reports 246 
of all included studies were screened for reports of additional studies. We also asked 247 
authors of studies identified from the published reviews to identify additional published 248 
studies and other trials in progress. 249 
 250 
Eligibility criteria  251 
12 
 
We used the same inclusion criteria reported by the Cochrane review,10 except we 252 
excluded studies conducted in adolescents and studies that did not report a depression 253 
outcome (see study protocol in eMethods 1):  254 
 255 
1) Population: Adults ≥18 years with depression or mixed anxiety and depressive 256 
disorder 257 
2) Intervention:  Collaborative care interventions: i. a multi-professional approach 258 
to patient care; ii. a structured management plan; iii. scheduled patient follow-259 
ups; and iv. enhanced inter-professional communication 260 
3) Comparison: Usual or enhanced usual care 261 
4) Outcome: Continuous depression scores 262 
5) Research design: RCTs or cluster RCTs 263 
 264 
Measuring depression and physical conditions  265 
All studies provided continuous depression scores measured using validated scales 266 
including the Beck Depression Inventory33 the Center for Epidemiologic Studies 267 
Depression Scale,34  the Hamilton Rating Scale for Depression35 and the Patient Health 268 
Questionnaire.36 We focused on short-term depression outcomes reported between 4 269 
and 6 months post-randomization. Depression scores were standardized within each 270 
study, using the baseline standard deviation and the follow-up mean score.  271 
 272 
At study-level, nine of the 36 comparisons recruited participants with a physical 273 
condition. 30 of the 36 comparisons reported data on the presence and number of 274 
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physical conditions at individual participant-level. Of these, the majority  of the 275 
comparisons (n=21) used validated comorbidity indices such as the Charlson Index,37 276 
while six used empirical lists of physical conditions. 17 comparisons identified the type of 277 
physical conditions among participants. Based on these data, we were able to create five 278 
categories of physical conditions: cancer (10 comparisons), cardiac disease (16 279 
comparisons), diabetes (17 comparisons), hypertension (11 comparisons), and 280 
respiratory disease (11 comparisons).  281 
 282 
Data extraction and preparation  283 
We contacted the study authors to obtain primary datasets for the following data: 284 
treatment group, age, gender, baseline and follow-up depression scores and number and 285 
types of physical conditions (see eTable 2). Received data were cleaned, converted into 286 
the same reporting format and aggregated into a single data set. Initial separate analyses 287 
on depression outcomes were conducted for each study to ensure that our analyses 288 
were consistent with those reported by the original study.  We also extracted data from 289 
the published reports of all the eligible studies using a standardized Excel data extraction 290 
form. We extracted data on populations, interventions, chronic conditions (used as 291 
moderator in the analyses), risk of bias, and outcome effect sizes. We compared studies 292 
which made data available to us with studies with unavailable data in terms of outcome 293 
effect sizes and moderator analyses.  294 
 295 
Missing data 296 
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We used multiple imputation techniques to obtain more complete datasets and to 297 
better protect against bias due to data missing at random mechanisms. Missing values for 298 
age and depression scores at follow up were imputed with a multivariate imputation 299 
algorithm (“mi impute mvn” in Stata 14) using Markov Chain Monte Carlo.38,39  This 300 
process produces several datasets, each of which is analyzed separately using the pre-301 
specified model; the results are then combined together using Rubin’s rules which 302 
accounts for uncertainty in imputed values.40 1000 new datasets with the observed and 303 
the imputed scores for age and depression at follow-up were generated based on values 304 
from study identification number, treatment group, baseline depression score, and sex. 305 
The range of imputed values was limited to the range of observed values of the 306 
variables. Time series and autocorrelation plots of the worst linear function were 307 
performed to monitor the convergence of the generated imputation algorithms.41,42 We 308 
examined whether baseline variables (study, treatment group, age, sex, and baseline 309 
depression scores) predicted missing data to confirm that the assumptions underlying 310 
imputations were met. Sensitivity analyses were performed using only cases with 311 
available data; no differences were detected in any of the reported results. 312 
  313 
Analysis  314 
One-step meta-analysis was undertaken because it is less susceptible to bias, is most 315 
efficient in terms of power and allows for sophisticated modelling of covariates (age, sex 316 
and baseline depression scores in this study).43,44 A one step IPD meta-analysis 317 
constructs a model for the hypothesized treatment-covariate relationships across all 318 
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individual participant datasets whilst statistically accounting for clustering at the level of 319 
each included dataset.45,46 320 
 321 
Appropriate mixed-effects models (fixed study-specific intercepts, random treatment 322 
effect and fixed study-specific effects for baseline depression) were used to meta-analyze 323 
the participant-level data and estimate the between and within-study variances and the 324 
effects of covariates.47 Clustered RCTs were statistically accounted for in the model by 325 
adhering to Sutton et al’s48 methodological recommendations. The Stata v14 command 326 
mixed was used through the ipdforest command, to summarize the evidence by study and 327 
obtain forest plots.49,50 A one-stage meta-analysis variant of the I2 statistic was used to 328 
assess heterogeneity.51 We examined the impact of covariates separately, building a 329 
model based on both statistical and theoretical criteria. Where studies included multiple 330 
treatment groups and a single control group, the treatment groups were treated as 331 
separate comparisons in the analyses, whereas the control groups were halved at 332 
random to avoid double counting in the analyses. In accordance with published 333 
guidelines, funnel plots were constructed to assess the potential for publication bias.52 334 
 335 
A number of pre-specified primary analyses were performed. One analysis examined a 336 
study-level moderator (binary variable; participants with physical conditions as part of 337 
the study’s inclusion criteria: yes=1; no=0). The other analyses examined moderators at 338 
patient-level including the presence (binary variable; present=1; 0=absent), number 339 
(continuous variable), and types of physical conditions (binary variables for each 340 
condition; present=1; 0=absent). 341 
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We conducted two secondary analyses to examine the robustness of the results. We 342 
assessed whether the results remained the same after controlling for the risk of bias 343 
scores of the studies (based on allocation concealment item). Allocation concealment 344 
was selected as an indicator of risk of bias because it is the most sensitive item to 345 
changes in the treatment effect especially when based on self-reported outcomes.53-55 346 
We also explored whether the main effects were influenced by the measure used to 347 
assess physical conditions (use of validated comorbidity severity indices). 348 
 349 
Results 350 
Figure 1 presents the flowchart of the study selection process.  A total of 76 (n=22,284) 351 
RCTs including 86 independent comparisons were eligible for inclusion in the IPD meta-352 
analysis. We found no evidence of asymmetry in the funnel plot for these studies  353 
(Egger’s regression test intercept = -0.54, SE= 0.42, P=0.21, eFigure 1). We collected 354 
data from 32 (n=11531; 52% of total number of participants) trials that included 37 355 
comparisons (see reference list in eResults 1). One RCT (a pilot study based on 49 356 
participants) was excluded from the analyses because it did not include data on age and 357 
gender,56 leaving a total of 36 comparisons. 569 (5%) individual cases were excluded 358 
from the analyses because of missing baseline values on depression or age leaving 10,962 359 
unique cases (of which n=1819; 16% were imputed using multiple imputations).  360 
 361 
Baseline characteristics and comparisons between available and unavailable 362 
data 363 
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18 studies were conducted in the US, 11 were conducted in Europe, 1 in Canada and 1 364 
in India. The majority of the participants were women (77%) with a mean age of 51 365 
(SD=15; range 17-97). Over three quarters of participants (78%) had at least one 366 
physical condition with a mean of 2.5 conditions (SD=2.3). No important issues were 367 
identified while checking the IPD data (see details about the characteristics of the 368 
studies in eTable 3 and 4). 369 
 370 
Available and non-available studies were compared in terms of population, intervention 371 
and risk of bias characteristics, as well as outcome data. We selected these specific 372 
characteristics based on the results of two previous reviews which applied meta-373 
regression analyses to identify moderators of the main effect of collaborative care 374 
interventions.12,16  As shown in Table 1, none of the differences identified were 375 
statistically significant except for the intervention content - a larger proportion of trials 376 
which incorporated psychological interventions made data available.  377 
 378 
What are the effects of collaborative care on depressive symptoms at 4-6 379 
months follow-up? 380 
Collaborative care is associated with a small but significant effect on depression 381 
outcomes compared with usual care (SMD =-0.22, 95% CI -0.25 to −0.18; I2=0.8%, 0.3% 382 
to 3.5%; see eFigure 2) equal to a drop of around 2-points on PHQ9 over and above the 383 
change in the controls. This effect size is smaller but not significantly different from the 384 
Cochrane review (-0.28, 95% CI -0.31 to -0.25; p=0.227 in Table 1).10 385 
 386 
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Is the effect of collaborative care on depression scores different in RCTs in 387 
which participants with physical conditions were part of the inclusion 388 
criteria?  389 
A statistically significant interaction was found between systematic identification of 390 
participants with physical conditions in the study and treatment effect (interaction 391 
coefficient=-0.12, 95% CI -0.23 to -0.02; Figure 2). RCTs that explicitly recruited people 392 
with physical conditions were associated with significantly larger treatment effects for 393 
depression (SMD= -0.29, 95% CI-0.37 to -0.21) compared with RCTs that did not 394 
explicitly recruit people with physical conditions (SMD=-0.19, 95% CI -0.23 to -0.15).  395 
 396 
The moderating effect of inclusion of physical conditions was even larger in trials with 397 
adequate concealment of allocation (interaction coefficient= -0.14, 95% CI -0.26 to -398 
0.02).  399 
 400 
Is the effect of collaborative care on depression moderated by the presence 401 
of physical conditions in patients?  402 
When we compared the effects of collaborative care in participants with and without 403 
physical conditions, the interaction term with the treatment effect was non-significant 404 
(interaction coefficient = 0.02, 95% CI= -0.10 to 0.13; Figure 3). We could not 405 
demonstrate any statistically significant moderating effect of the presence of physical 406 
conditions on depression outcomes at follow-up (effect in those with physical conditions 407 
SMD= -0.21, 95% CI -0.27 to -0.15, in those without SMD= -0.23, 95% CI -0.32 to -408 
0.12).  409 
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This result was not sensitive to allocation concealment ratings (adequate; interaction 410 
coefficient -0.06, 95% CI -0.04 to 0.02), or to the measure used to assess physical 411 
conditions (validated; 0.05, 95% CI -0.08 to 0.10).  412 
 413 
Is the effect of collaborative care on depression scores moderated by the 414 
number of physical conditions?  415 
The interaction term between number of physical conditions and treatment effect was 416 
non-significant (interaction coefficient = 0.01, 95% CI= -0.01 to 0.02; Figure 4). This 417 
finding suggests that the improvement of depression scores at follow-up does not differ 418 
according to numbers of physical conditions. 419 
 420 
The interaction effect was not significantly affected by the allocation concealment rating 421 
(interaction coefficient -0.00, 95% CI -0.03 to 0.03), or by the measure used to assess 422 
physical conditions (interaction coefficient -0.01, 95% CI -0.04 to 0.02). 423 
 424 
Is the effect of collaborative care on depressive symptoms moderated by 425 
different types of physical conditions in patients? 426 
We found no evidence that the effects of collaborative care on depression outcomes 427 
are moderated by the types of physical conditions among participants. None of the 428 
interaction effects between treatment effect and types of physical conditions were 429 
significant: cancer (interaction coefficient = 0.11, 95% CI -0.02 to 0.22), cardiac disease 430 
(interaction coefficient = -0.02, 95% CI -0.14 to 0.09), diabetes (interaction coefficient =-431 
0.02, 95% CI -0.08 to 0.09), hypertension (interaction coefficient = -0.09, 95% CI -0.21 432 
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to 0.03), and respiratory disease (interaction coefficient = -0.08, 95% CI -0.21 to 0.07). 433 
These findings suggest that the benefits derived by collaborative care do not differ 434 
significantly across subgroups of people with certain types of physical conditions. None 435 
of the interaction effects were affected by allocation concealment or by the measure 436 
used to assess physical conditions.  437 
 438 
Discussion 439 
Analyzing data from 36 comparisons of collaborative care and nearly 11,000 participants, 440 
this IPD meta-analysis showed that collaborative care is associated with significant short 441 
term improvements in depression outcomes across all people with or without comorbid 442 
physical conditions. At study-level, trials which only recruited participants with 443 
comorbid physical conditions were associated with larger treatment effects compared 444 
with trials which did not, confirming previous findings.12,15   However, when a more 445 
accurate analysis at individual participant-level was undertaken, the presence, number 446 
and type of physical conditions did not moderate the main effect of collaborative care 447 
on depression outcomes. Overall, the findings of this IPD meta-analysis do not support 448 
existing recommendations based on meta-analyses of aggregate data that collaborative 449 
care should only be considered for patients with comorbid depression and physical 450 
conditions. Our findings highlight the importance of undertaking IPD analyses in 451 
developing rigorous recommendations, especially for subgroups of complex patients.  452 
 453 
Strengths and limitations  454 
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This study is the most methodologically rigorous test of the influence of physical 455 
conditions on the effects of collaborative care on depression outcomes.26,57 However, 456 
there are a number of limitations. IPD meta-analysis remains vulnerable to important 457 
sources of bias including publication, study/reviewer selection and data availability bias.52 458 
No funnel plot asymmetry was detected suggesting that publication bias is not likely to 459 
be present in the overall dataset. Study selection bias was minimized by including studies 460 
through multiple sources (i.e. an existing gold standard Cochrane review, top-up 461 
database searches, and author requests) using strict pre-specification of trial eligibility 462 
criteria. These efforts facilitated access to data from approximately half of participants 463 
included in published RCTs of collaborative care for depression, which is below the 464 
recommended recruitment target (80% of data requested).52 We observed some 465 
differences between available and non-available studies, but these differences rarely 466 
reached statistical significance. For example, the overall effect size was smaller than that 467 
found in the previous Cochrane review. This difference is likely to be explained by the 468 
fact that less than half of all collaborative care trials were included in this IPD analysis 469 
and these were generally larger than trials that were not included. It is important to 470 
continue to develop effective methods and agreements about data sharing to ensure that 471 
future analyses have better access to data. 472 
 473 
Another limitation is that the evaluation of physical conditions was not pursued in an 474 
entirely consistent manner across trials. Most of the trials assessed the number of 475 
physical conditions using validated comorbidity indices which contain extensive lists of 476 
physical conditions, but some trials used less comprehensive lists of physical conditions 477 
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which were empirically devised.37  Although we separately examined the influence of 5 478 
common physical conditions, participants could have more than one of these conditions. 479 
The experience and interactions of multiple concordant or discordant conditions58 is 480 
another factor that might differentiate why people might respond differently to 481 
depression treatment.  482 
 483 
The use of multiple mixed-effects regression analyses of individual patient data and 484 
controlling for covariates significantly reduces the possibility of bias present in aggregate 485 
data meta-analyses (e.g. ecological fallacy or Simpson paradox). 26,57,59-61 However, we 486 
recommend interpreting these findings cautiously as some of these biases might still 487 
operate.   488 
 489 
Finally, there were important between-study variations including intervention content 490 
(collaborative care is generally heterogeneous)10 and depression measures. However, 491 
these study-level variations are unlikely to influence the participant-level analyses that 492 
showed that chronic physical conditions do not moderate the effectiveness of 493 
collaborative care. A post-hoc sensitivity analysis indicated that the results were similar 494 
irrespective of using self-reported or observer-rated measures for depression.  495 
 496 
Comparison of this study with previous systematic reviews 497 
Previous systematic reviews have examined moderators of the effect of collaborative 498 
care on depression outcomes but were based on aggregate data and used meta-499 
regressions.12,16 Improved depressive outcomes were predicted by inclusion of 500 
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psychological interventions and the use of antidepressant medication was predicted by 501 
recruiting people with physical conditions in trials.12 Based on these findings it was 502 
proposed that patients with physical conditions may derive greater benefits from 503 
collaborative care compared with patients without physical conditions. As noted earlier, 504 
these analyses are a less robust basis for decision-making because they are insensitive to 505 
variation in physical conditions at the level of individual patients. Indeed, in this IPD 506 
meta-analysis, we found no support for this hypothesis.  507 
 508 
Implications for clinicians, policymakers and researchers 509 
This study suggests that patients with and without comorbid physical conditions gain 510 
important improvements in depression outcomes from collaborative care. As such our 511 
findings do not support the recommendation by NICE that collaborative care should 512 
only be considered for people with depression and comorbid physical conditions with 513 
functional impairment.15  Limiting collaborative care to people with depression and 514 
comorbid physical conditions does not appear to be a reasonable policy 515 
recommendation with important implications for patient benefit. IPD meta-analyses are 516 
under-used in clinical guidelines and the next iteration of guidelines for depression could 517 
be improved by using the most reliable evidence available. 59 518 
 519 
Given that the effectiveness of collaborative care is confirmed, future research should 520 
focus on understanding how to optimize the delivery and the outcomes of collaborative 521 
care.  For instance, based on recent evidence, the systematic measurement and 522 
management of physical health outcomes along with mental health outcomes has the 523 
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potential to boost the effectiveness of collaborative care in people with physical 524 
comorbidities.60 On the other hand, the overall treatment benefits associated with 525 
collaborative care are modest.10 It is therefore legitimate to suggest that future 526 
treatment policy guidelines should also be grounded on the comparative cost-527 
effectiveness of collaborative care to other types of interventions. 528 
 529 
Conclusion 530 
This IPD meta-analysis represents the most rigorous and precise analysis to date about 531 
the extent to which physical conditions influence the effectiveness of collaborative care 532 
on depression outcomes.  People with depression derive significant benefits from 533 
collaborative care regardless of the presence, number, or type of comorbid physical 534 
conditions. The core challenge now is to understand how to deliver these interventions 535 
at scale in routine settings and to better operationalize the treatment outcomes to 536 
maximize patient benefits. 537 
 538 
Acknowledgments 539 
This study was funded by the UK National Institute of Health Research (NIHR) School 540 
for Primary Care Research. The research team members were independent from the 541 
funding agency. The views expressed in this publication are those of the authors and not 542 
necessarily those of the National Health Service, the NIHR, or the Department of 543 
Health. The funders had no role in the design and conduct of the study; the collection, 544 
management, analysis, and interpretation of the data; and the preparation, review, or 545 
approval of the manuscript. 546 
25 
 
Dr Peter Coventry had full access to all of the data in the study and takes responsibility 547 
for the integrity of the data and the accuracy of the data analysis. 548 
 549 
We would like to acknowledge the important contribution of Professor Wayne Katon 550 
(passed away in March 2015 before approving this manuscript), who provided us access 551 
to six datasets of collaborative care trials. We also thank Professor Harm van Marwijk 552 
and Dr. Penny Bee for commenting on drafts of this manuscript.  553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
26 
 
References 570 
1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 571 
diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the 572 
Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2197-2223. 573 
2. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease 574 
attributable to mental and substance use disorders: findings from the Global 575 
Burden of Disease Study 2010. The Lancet. 2013;382(9904):1575-1586. 576 
3. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, 577 
chronic diseases, and decrements in health: results from the World Health 578 
Surveys. The Lancet. 2007;370(9590):851-858. 579 
4. Freedland KE, Carney RM. Depression as a risk factor for adverse outcomes in 580 
coronary heart disease. BMC medicine. 2013;11:131. 581 
5. Carney RM, Blumenthal JA, Catellier D, et al. Depression as a risk factor for 582 
mortality after acute myocardial infarction. Am J Cardiol. 2003;92(11):1277-1281. 583 
6. Panagioti M, Stokes J, Esmail A, et al. Multimorbidity and Patient Safety Incidents 584 
in Primary Care: A Systematic Review and Meta-Analysis. PloS One. 585 
2015;10(8):e0135947. 586 
7. Dickens C, Katon W, Blakemore A, et al. Does depression predict the use of 587 
urgent and unscheduled care by people with long term conditions? A systematic 588 
review with meta-analysis. J Psychosom Res. 2012;73(5):334-342. 589 
8. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A. Long-term 590 
conditions and mental health. The cost of co-morbidities. London: King's Fund and 591 
Centre for Mental Health;2012. 592 
27 
 
9. Gunn J, Diggens J, Hegarty K, Blashki G. A systematic review of complex system 593 
interventions designed to increase recovery from depression in primary care. 594 
BMC Health Serv Res. 2006;6:88. 595 
10. Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and 596 
anxiety problems. The Cochrane database of systematic reviews. 597 
2012;10:CD006525. 598 
11. Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner roles in chronic 599 
illness: the specialist, primary care physician, and the practice nurse. General 600 
Hospital Psychiatry. 2001;23(3):138-144. 601 
12. Coventry PA, Hudson JL, Kontopantelis E, et al. Characteristics of effective 602 
collaborative care for treatment of depression: a systematic review and meta-603 
regression of 74 randomised controlled trials. PloS One. 2014;9(9):e108114. 604 
13. Community Preventive Services Task F. Recommendation from the Community 605 
Preventive Services Task Force for Use of Collaborative Care for the 606 
Management of Depressive Disorders. Am J Prevent Med. 2012;42(5):521-524. 607 
14. Thota AB, Sipe TA, Byard GJ, et al. Collaborative Care to Improve the 608 
Management of Depressive Disorders: A Community Guide Systematic Review 609 
and Meta-Analysis. Am J Prevent Med. 2012;42(5):525-538. 610 
15. NICE. Depression in Adults with a Chronic Physical Health Problem: Treatment 611 
and Management. Leicester: British Psychological Society; 2010. 612 
16. Bower P, Gilbody S, Richards D, Fletcher J, Sutton A. Collaborative care for 613 
depression in primary care. Making sense of a complex intervention: systematic 614 
review and meta-regression. Br J Psychiatr. 2006;189:484-493. 615 
28 
 
17. Bartels SJ, Coakley EH, Zubritsky C, et al. Improving access to geriatric mental 616 
health services: A randomized trial comparing treatment engagement with 617 
integrated versus enhanced referral care for depression, anxiety, and at-risk 618 
alcohol use. Am J Psychiat. 2004;161(8):1455-1462. 619 
18. Blanchard MR, Waterreus A, Mann AH. The effect of primary care nurse 620 
intervention upon older people screened as depressed. Intern J Geriatr Psychiatr. 621 
1995;10(4):289-298. 622 
19. Bruce ML, Ten Have TR, Reynolds CF, 3rd, et al. Reducing suicidal ideation and 623 
depressive symptoms in depressed older primary care patients: a randomized 624 
controlled trial. JAMA. 2004;291(9):1081-1091. 625 
20. Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-626 
based depression treatment in older adults - A randomized controlled trial. 627 
JAMA. 2004;291(13):1569-1577. 628 
21. Ell K, Unutzer J, Aranda M, Gibbs NE, Lee PJ, Xie B. Managing depression in 629 
home health care: a randomized clinical trial. Home Health Care Serv Quarterly. 630 
2007;26(3):81-104. 631 
22. McCusker J, Cole M, Yaffe M, et al. Project Direct: Pilot Study of A Collaborative 632 
Intervention for Depressed Seniors. Can J Com Mental Health. 2008;27(2):201-633 
218. 634 
23. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-635 
life depression in the primary care setting: a randomized controlled trial. JAMA. 636 
2002;288(22):2836-2845. 637 
29 
 
24. Cole MG, McCusker J, Elie M, Dendukuri N, Latimer E, Belzile E. Systematic 638 
detection and multidisciplinary care of depression in older medical inpatients: a 639 
randomized trial. Can Med Assoc J. 2006;174(1):38-44. 640 
25. Chew-Graham CA, Lovell K, Roberts C, et al. A randomised controlled trial to 641 
test the feasibility of a collaborative care model for the management of 642 
depression in older people. Brit J Gen Pract. 2007;57(538):364-370. 643 
26. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. 644 
Statistical analysis of individual participant data meta-analyses: a comparison of 645 
methods and recommendations for practice. PloS one. 2012;7(10):e46042. 646 
27. Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how 647 
much do we need for reliable and informative meta-analyses? BMJ. 648 
1994;309(6960):1007-1010. 649 
28. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: 650 
rationale, conduct, and reporting. BMJ. 2010;340:c221. 651 
29. Harrison M, Reeves D, Harkness E, et al. A secondary analysis of the moderating 652 
effects of depression and multimorbidity on the effectiveness of a chronic disease 653 
self-management programme. Patient Educ Counsel. 2012;87(1):67-73. 654 
30. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentelange M, Martin DK. The 655 
effects of comorbidity on the benefits and harms of treatment for chronic 656 
disease: a systematic review. PLoS One. 2014;9(11). 657 
31. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic 658 
Review and Meta-Analyses of individual participant data: the PRISMA-IPD 659 
Statement. JAMA. 2015;313(16):1657-1665. 660 
30 
 
32. Tierney JF, Vale C, Riley R, et al. Individual Participant Data (IPD) Meta-analyses 661 
of Randomised Controlled Trials: Guidance on Their Use. Plos Med. 2015;12(7). 662 
33. Beck AT, Steer RA. Internal consistencies of the original and revised Beck 663 
Depression Inventory. J Clin Psychol. 1984;40(6):1365-1367. 664 
34. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the 665 
General Population. Appl Psychol Meas. 1977;1(3):385-401. 666 
35. Hamilton M. Rating depressive patients. J Clin Psychiatr. 1980;41:21-24. 667 
36. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression 668 
severity measure. J Gen Intern Med. 2001;16(9):606-613. 669 
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 670 
prognostic comorbidity in longitudinal studies: development and validation. J 671 
Chronic Dis. 1987;40(5):373-383. 672 
38. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling 673 
missing repeated measurements in obesity trial data: beyond LOCF. Obesity Rev. 674 
2003;4(3):175-184. 675 
39. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle 676 
introduction to imputation of missing values. J Clin Epidemiol. 2006;59(10):1087-677 
1091. 678 
40. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley & 679 
Sons; 1987. 680 
41. Schafer J. Analysis of incomplete multivariate data. Chapman and Hall1997. 681 
42. Stata Press. Multiple-imputation reference manual. Stata Press2014. 682 
31 
 
43. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient 683 
data: is there a difference? Lancet. 1993;341(8842):418-422. 684 
44. Vickers AJ, Cronin AM, Maschino AC, et al. Acupuncture for chronic pain: 685 
individual patient data meta-analysis. Arch Intern Med. 2012;172(19):1444-1453. 686 
45. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: 687 
rationale, conduct, and reporting. BMJ. 2010;340(7745):521-525. 688 
46. Simmonds M, Higgins J. Covariate heterogeneity in meta‐analysis: Criteria for 689 
deciding between meta‐regression and individual patient data. Stat Med. 690 
2007;26(15):2982-2999. 691 
47. Whitehead A. Meta-analysis of Controlled Clinical Trials. New York: John Wiley & 692 
Sons; 2002. 693 
48. Sutton AJ, Kendrick D, Coupland CA. Meta‐analysis of individual‐and aggregate‐694 
level data. Stat Med. 2008;27(5):651-669. 695 
49. StataCorp. Stata Statistical Software: Release 12. College Station: StataCorp LP; 696 
2011. 697 
50. Kontopantelis E, Reeves D. A short guide and a forest plot command (ipdforest) 698 
for one-stage meta-analysis. Stata J. 2013;13(3):574-587. 699 
51. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 700 
2002;21(11):1539-1558. 701 
52. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and 702 
unavailable data in meta-analyses using individual participant data: a database 703 
survey. BMJ. 2012;344:d7762. 704 
32 
 
53. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool 705 
for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928 706 
54. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. 707 
Dimensions of methodological quality associated with estimates of treatment 708 
effects in controlled trials. JAMA. 1995;273(5):408-412. 709 
55. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact 710 
of allocation concealment on conclusions drawn from meta-analyses of 711 
randomized trials. Int J Epidemiol. 2007;36(4):847-857. 712 
56. McMahon L, Foran KM, Forrest SD, et al. Graduate mental health worker case 713 
management of depression in UK primary care: a pilot study. Br J Gen Pract. 714 
2007;57(544):880-885. 715 
57. Tierney JF, Pignon J-P, Gueffyier F, et al. How individual participant data meta-716 
analyses have influenced trial design, conduct, and analysis. J Clin Epidemiol. 717 
2015;68(11):1325-35. 718 
58. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. 719 
Diabetes Care. 2006;29(3):725-731. 720 
59. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. 721 
Meta-analysis of individual patient data from randomized trials: a review of 722 
methods used in practice. Clin Trials. 2005;2(3):209-217. 723 
60. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed 724 
to treat. BMC Med Res Method. 2002;2:3. 725 
61. Kievit RA, Frankenhuis WE, Waldorp LJ, Borsboom D. Simpson's paradox in 726 
psychological science: a practical guide. Frontiers Psychol. 2013;4:513. 727 
33 
 
62.      Vale CL, Rydzewska LH, Rovers MM, et al. Uptake of systematic reviews and 728 
meta-analyses based on individual participant data in clinical practice guidelines: 729 
descriptive study. BMJ. 2015;350:h1088. 730 
63. McGregor M, Lin EH, Katon WJ. TEAMcare: an integrated multicondition 731 
collaborative care program for chronic illnesses and depression. J  Ambul Care 732 
Manag. 2011;34(2):152-162. 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
 749 
 750 
34 
 
 Figure 1: PRISMA flowchart 751 
Figure legend: Flowchart of the inclusion of studies in the review 752 
 753 
Figure 2: Study-level analysis examining the effect of the presence chronic physical 754 
conditions on the effectiveness of collaborative care  755 
Figure legend: Meta-analysis forest plot of study-level data and pooled effects across 36 756 
comparisons. 2a: Studies which did not explicitly recruit patients with chronic physical conditions. 757 
2b: studies which explicitly recruited patients with chronic physical conditions (2b) Mixed effects 758 
model used. 95% CI = 95% confidence intervals 759 
 760 
Figure 3: Individual participant-level analysis examining the effect of the presence of 761 
chronic physical conditions on the effectiveness of collaborative care.  762 
Figure legend: Meta-analysis forest plot of individual participant data and pooled effects across 763 
30 comparisons. 3a: Studies in which participants did not have a chronic physical condition. 3b: 764 
Studies in which participants had a chronic physical condition. Mixed effects model used. 95% 765 
CI = 95% confidence intervals 766 
 767 
Figure 4: Individual participant-level analysis examining the effect of the number of 768 
chronic physical conditions on the effectiveness of collaborative care  769 
Figure legend: Meta-analysis forest plot of individual participant data and pooled effects across 770 
30 comparisons. 4a: Main effect of the individual participant data analysis. 4b: Interaction 771 
effect of the study group and the number of physical chronic conditions. Mixed effects model 772 
used. 95% CI = 95% confidence intervals 773 
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Table 1. Comparison of studies providing data for the IPD analyses and those 774 
not providing data 775 
Variable Unavailable (n=49) Available (36) Statistical test  
Country (US) 36 (78) 23 (62) X2 (1, 85) = 3.17, P=0.08  
Publication date 
Mean (SD) 
Median (range) 
 
2006 (4.03) 
2007 (1995 to 2013) 
 
2007 (5.29) 
2008 (1995 to 2015) 
 
t(83)=1.01, P=0.32 
Recruitment method  
Systematic n (%) 
 
41 (84) 
 
31 (84) 
 
X2 (1, 85) = 0.01, P=0.98 
Chronic physical condition 
Present n (%) 
 
12 (24) 
 
9 (24) 
 
X2 (1, 85) = 0.01, P=0.97 
Intervention content 
Psychological or both n (%) 
 
20 (41) 
 
28 (76) 
 
X2 (1, 85) = 12.79, P<0.01 
Supervision frequency  
Scheduled mean (SD) 
 
1.64 (0.82) 
 
1.76 (0.91) 
 
t(83)=0.65, P=0.52 
Allocation concealment         
low risk n (%) 
 
30 (61) 
 
18 (49) 
 
X2 (1, 85) = 3.17, P=0.24 
Sample size  
Mean (SD)  
Median (range) 
 
220 (305) 
165 (23 to 1570) 
 
292 (192) 
227 (64 to 783) 
t(83)=1.63, P=0.11 
Effect size;  SMD (SE) -0.32 (0.31) 
(95%CI -0.40 to – 0.23) 
-0.24 (0.30) 
(95%CI -0.29 to – 0.10) 
t(83)=1.22, P=0.23 
  776 
